This commentary discusses a paper by Cocco et al. that addresses the treatment of multiple sclerosis (MS) with the drug mitoxantrone in women of childbearing age. This is a very important issue, as mitoxantrone is thought to be associated with the development of chemotherapy-induced amenorrhea (CIA) in women with MS. CIA is a condition characterized by cessation of menstrual bleeding that can be associated with either temporary or permanent infertility. In the study, a clear cumulative dose effect of mitoxantrone on the development of CIA was demonstrated. The risk of CIA was also shown to increase with age. However, the incidence of CIA was lower in women who took estroprogestinic hormones concurrently with mitoxantrone. The authors concluded that mitoxantrone may markedly affect reproductive capacity in women with MS and that estroprogestinic drugs should be administered alongside mitoxantrone to guard against these possible effects. The potential for estroprogestinic drugs to guard against CIA is intriguing and warrants further investigation. Mitoxantrone, a drug traditionally used to treat cancer, is now used as a treatment in patients with multiple sclerosis (MS) who have relatively aggressive disease-specifically, progressive relapsing disease that generally has responded sub optimally to treatment with interferon β (IFNβ) or glatiramer acetate. Mitoxantrone is, however, thought to be associated with the development of chemotherapyinduced amenorrhea (CIA). This finding is worrying, as MS is not tradition ally associated with CIA or early menopause, and the fertility of women with MS is thought to be normal. 1 Numerous autoimmune diseases, including MS, 2 predominantly affect women, and these women are often of childbearing age; there fore, finding a treatment that could prevent the development of CIA in these patients would be of major importance. Cocco et al. 3 have demon strated a cumulative dose effect of mitoxantrone on the development of CIA and that this risk increases with age. These findings were important to document but are not surprising. However, intriguing novel data were also presented in this paper that showed that those women who were taking estrogen or progesterone during treatment with mitoxantrone had a decreased incidence of CIA and menopause compared with those not taking estroprogestinic drugs.
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Cocco and colleagues investigated the inci dence of CIA in 189 women with MS who were treated with mitoxantrone (for at least 3 treatment cycles) before the age of 45 years. As reported through an 'ad hoc' questionnaire, 48 (26%) of the patients subsequently developed CIA. The incidence of CIA rose with increases in mitoxantrone dose (by 2% per mg/m 2 of cumula tive dose) and age (by 18% for each additional year of age) but was reduced in women who had taken estroprogestinic hormones concur rently with mitoxantrone. In this study, relative to the timing of mitoxantrone administration, 54% of the patients had been previously treated, 4% concurrently treated, and 44% subsequently treated with IFNβ. Treatment with IFNβ during pregnancy has been associated with menstrual abnormalities and poor pregnancy outcomes in MS 4 (although persistence of these effects beyond discontinuation of this treatment has not been
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The authors declared no competing interests. demonstrated). Absence of treatment with IFNβ in women who that took estroprogestinic drugs could, therefore, have confounded the findings with regard to estroprogestinic hormones. Thus, it would be useful to know whether the frequencies of IFNβ treatment were equally distributed between those who had and those who had not taken estroprogestinic hormones-data not reported by Cocco et al. Assuming that there was a random distribution of IFNβ treatment, and that this was not a confounding factor in the finding of protection from CIA with estropro gestinic hormones, this apparent protective effect of hormones clearly warrants further attention.
The authors hypothesized that the protective effect against CIA of estroprogestinic hormones taken concurrently with mitoxantrone could result from the hormones' inhibition of the ovarian cycle. 3 They base their hypothesis on a paper that described a higher incidence of CIA when chemotherapeutic drugs were administered during the follicular phase of the cycle. 5 The situ ation may, however, be more complex. Generally speaking, in relatively young women, approxi mately 20-30 primordial follicles become acti vated each month from the oocyte pool. Of these activated follicles, one will become dominant and mature during each cycle. Chemotherapy may act to reduce the oocyte pool before activation, interfere with the initial activation of follicles, or interfere with follicular maturation and development of the dominant follicle. These are not mutually exclusive events. Infertility during concurrent chemotherapy would support the theory of interference with either follicular activation or maturation. On the other hand, when menstrual cycles return after completion of chemotherapy, only to be followed by a reduced ability for subsequent conception and an increased risk of early menopause, this would suggest that chemotherapeutic agents lead to a reduced oocyte pool before follicular activation.
If treatment with estroprogestinic hormones is indeed protective in CIA, as described by Cocco et al., it should be determined whether oocytes express estrogen receptors or progesterone receptors, either before or during follicular activation. 6 Estrogens in particular have been shown to have potent antiapoptotic properties in the brain. 7 Thus, it is possible that there are direct effects of estrogens in protecting against chemotherapyinduced apoptosis of oocytes.
Alternatively, there may be indirect effects whereby estrogens act on estrogen receptors in ovarian stromal cells that support oocytes. These questions can now be answered in animal models through use of conditional celltargeted knock outs of estrogen receptor alpha or beta. Deter mining the mechanism by which hormones exert their protective effect against CIA could lead to specific targeting of the ovarian cell of interest by treatments that use estrogenreceptorspecific ligands. The protective effects could, thereby, be maximized and the toxic effects in other cells and organ systems minimized. 8 In conclusion, the finding that estropro gestinic hormones may be protective against chemotherapyinduced infertility warrants confir mation in further studies. If proven, then investi gation into the mechanisms of this protection would be important to discern, since this could lead to prevention of a major problem for women with MS or other autoimmune diseases who are treated with chemotherapeutic agents.
